Eucreas

Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequately controlled on metformin alone or in patients who are already treated with the components as separate tablets.

Eucreas is available as film-coated tablets containing vildagliptin 50mg plus metformin hydrochloride 850mg or 1000mg.

Eucreas should be given twice daily. Patients receiving vildagliptin and metformin as separate tablets may switch to the equivalent Eucreas tablet; those on metformin alone should be initiated on the strength of Eucreas tablet that matches their current metformin dose.

View Eucreas drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more